Mobiosense Corp.
Update：2026/09/15
Industries
Main Industry
Health Care
Main Product/Service
Mobiosense Corp. currently manufactures and has clinically validated the "Mobiosense™ COVID-19 Isothermal Nucleic Acid Detection Kit" and the "MuTest™ African Swine Fever Detection Kit". The core technology of these products is isothermal nucleic acid amplification. Specifically, by utilizing a unique primer design and polymerase in the formulation, the nucleic acid amplification reaction can occur at a constant temperature. This characteristic allows the technology to overcome the limitation of polymerase chain reaction (PCR), which requires repeated thermal cycling. Furthermore, reverse transcription can be performed simultaneously during the nucleic acid amplification reaction, enabling a more diverse range of compatible downstream detection methods.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2015
Unified Business No.
24950178
Status
Active
Number of Employees
4
Total Paid-in
Capital
12,700,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
